Amorfix and Cangene collaborate on development of therapeutic antibodies for oncology

December 13, 2012

Amorfix Life Sciences Ltd. announced today that it has established a collaboration with CNJ Holdings Inc., a wholly-owned subsidiary of Cangene Corporation, for the identification and development of therapeutic antibodies against proprietary disease specific epitopes (DSEs) identified using Amorfix's ProMIS™ discovery technology for the treatment of various oncology indications.

"This collaboration represents the ideal situation where two companies come together with complementary expertise, resources and technology in a united effort to identify and develop novel antibody therapeutics for the treatment of cancer", said Dr. Robert Gundel, Amorfix President and CEO. "Establishing partnerships and strategic alliances to accelerate the discovery, development and commercialization of therapeutic antibodies is part of our overall strategy to build our product pipeline."

Click here for the article.

Share This Story


"We are excited about this collaboration with Amorfix which brings new energy to our R&D pipeline development efforts. This is an opportunity to leverage our core competencies to accelerate the development of therapeutic antibodies to novel targets in the oncology space." -John Sedor, President and CEO, Cangene.